Gujarat Themis Biosyn Limited (BOM: 506879)

Market Cap	32.05B
Revenue (ttm)	1.54B
Net Income (ttm)	527.01M
Shares Out	108.97M
EPS (ttm)	4.83
PE Ratio	60.93
Forward PE	n/a
Dividend	0.67 (0.23%)
Ex-Dividend Date	Jul 15, 2024

Volume	26,474
Open	296.90
Previous Close	293.35
Day's Range	290.30 - 299.90
52-Week Range	108.20 - 390.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 11, 2024

About Gujarat Themis Biosyn

Gujarat Themis Biosyn Limited engages in the manufacture of pharmaceuticals and medicinal chemicals in India. The company offers bulk drugs on job work basis in India. Its products include Rifamycin-S, an intermediate for the treatment of tuberculosis; Rifamycin-O; and Lovastatin. The company was incorporated in 1981 and is based in Mumbai, India.

• Industry: Medicinal Chemicals and Botanical Products
• Founded: 1981
• Employees: 159
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 506879

Financial Performance

In 2023, Gujarat Themis Biosyn's revenue was 1.70 billion, an increase of 14.45% compared to the previous year's 1.48 billion. Earnings were 591.63 million, an increase of 2.06%.